Financial News
ProQR Therapeutics N.V. - Ordinary Shares (NQ: PRQR )
2.420
+0.150
(+6.61%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
All News about ProQR Therapeutics N.V. - Ordinary Shares
![](https://investorplace.com/wp-content/uploads/2021/12/sklz-1600-1024x576.png)
![](https://cdn.benzinga.com/files/images/story/2022/12/22/image20.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/10/electric-vehicle-charging-ev-1600.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/08/12/aapharma_15.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/08/11/aapharma_10.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2020/03/mrna1600.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/12/22/image21.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/12/22/image20.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/12/22/prqr_logo_light__4f1694c259509189da1a8fac435f46e0.png?width=1200&height=800&fit=crop)
ProQR Therapeutics Shares Soar As Eli Lilly Expands RNA Collaboration
December 22, 2022
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street-washington-statue.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_10543.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_7025.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/04/13/aapharma_5.png?width=1200&height=800&fit=crop)
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
December 22, 2022
Via GlobeNewswire
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_2607.jpeg)
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
ProQR Announces Third Quarter 2022 Operating and Financial Results
November 09, 2022
Via GlobeNewswire
![](https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png)
![](https://cdn.benzinga.com/files/images/story/2022/05/04/lab-5740505_1920.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_24907.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/05/02/biotech7.jpg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/06/28/image22.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_7620.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/04/29/lab-5740505_1920.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_6909.jpeg)
![](https://cdn.benzinga.com/files/images/story/2022/04/13/lab-5740505_1920.jpg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/analyst_ratings_image_2628.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_2810.jpeg)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.